Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1028-1036

  Dudakovic, Amel ^a   Wiemer, Andrew J ^b   Lamb, Kimberly M ^a   Vonnahme, Laura A ^a   Dietz, Sara E ^a   Hohl, Raymond J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; ETOPOSIDE; FARNESYL DIPHOSPHATE; FARNESYL TRANS TRANSFERASE; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; GGTI 298; MEVINOLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAS PROTEIN; ZARAGOZIC ACID A; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL STRAIN K 562; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; K562 CELLS; TERPENES;

EID: 40849142358     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.132217     Document Type: Article

References (40)

1. Andersen JM and Dietschy JM (1978) Relative importance of high and low-density lipoproteins in the regulation of cholesterol-synthesis in the adrenal-gland, ovary, and testis of the rat. J Biol Chem 253:9024-9032.
2. Brown MS and Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21:505-517.
3. Brown MS and Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340.
4. Burridge K and Doughman R (2006) Front and back by Rho and Rac. Nat Cell Biol 8:781-782.
5. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Del Prete S, Tagliaferra P, Tassone P, et al. (2004) The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by zoledronic acid (Zometa) and pamidronate. Oncogene 23:6900-6913.
6. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
7. Crick DC, Andres DA, and Waechter CJ (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237:483-487.
8. Dorsey JK and Porter JW (1968) The inhibition of mevalonic kinase by geranyl and farnesyl pyrophosphates. J Biol Chem 243:4667-4670.
9. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, and Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
10. Edwards PA and Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68:157-185.
11. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, and Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 96:133-138.
12. Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430.
13. Green JR and Clezardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25:S3-S9.
14. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33.
15. Holstein SA and Hohl RJ (2001a) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25:651-660.
16. Holstein SA and Hohl RJ (2001b) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141-149.
17. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, and Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134.
18. + leukemia activity of imatinib mesylate. Blood 102:2229-2235.
19. Lebowitz PF, Sakamuro D, and Prendergast GC (1997) Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713.
20. Lerner EC, Qian Y, Hamilton AD, and Sebti SM (1995) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-26773.
21. Lewis KA, Holstein SA, and Hohl RJ (2005) Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res 29:527-533.
22. Licata AA (2005) Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668-677.
23. Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, and Wiemer DF (2007) Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorg Med Chem 15:1959-1966.
24. Meigs TE and Simoni RD (1997) Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch Biochem Biophys 345:1-9.
25. Miquel K, Pradines A, Terce F, Selmi S, and Favre G (1998) Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem 273:26179-26186.
26. Pérez-Sala D and Mollinedo F (1994) Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209-1215.
27. Reszka AA and Rodan GA (2004) Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 4:711-719.
28. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, and Tonini G (2006) Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 3:325-338.
29. Schmidmaier R, Simsek M, Baumann P, Emmerich B, and Meinhardt G (2006) Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 17:621-629.
30. Schreiber V, Dantzer F, Ame JC, and de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528.
31. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, and Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98:665-672.
32. Shull LW, Wiemer AJ, Hohl RJ, and Wiemer DF (2006) Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem 14:4130-4136.
33. Swanson KM and Hohl RJ (2006) Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets 6:15-37.
34. Takai Y, Sasaki T, and Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208.
35. Thornberry NA and Lazebnik Y (1998) Caspases: enemies within. Science 281:1312-1316.
36. Tong H, Holstein SA, and Hohl RJ (2005) Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 336:51-59.
37. van Beek E, Lowik C, van der Pluijm G, and Papapoulos S (1999a) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729.
38. van Beek E, Pieterman E, Cohen L, Lowik C, and Papapoulos S (1999b) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494.
39. Voziyan PA, Goldner CM, and Melnykovych G (1993) Farnesol inhibits phosphatidylcholine biosynthesis in cultured-cells by decreasing cholinephosphotransferase activity. Biochem J 295:757-762.
40. Wiemer AJ, Tong HX, Swanson KM, and Hohl RJ (2007) Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun 353:921-925.